

1

2

3

4

The Pathogenesis of Bisphosphonate Related Osteonecrosis of the Jaw: So Many

5

Hypotheses so Few Data

6

7

Matthew R. Allen ¹ and David B. Burr ^{1,2,3}

8

9

¹Department of Anatomy and Cell Biology

10

²Department of Orthopaedic Surgery, Indiana University School of Medicine

11

³Biomedical Engineering Program

12

Indiana University-Purdue University, Indianapolis

13

Indianapolis, IN 46202

14

15

16

17

18

19

20

Corresponding Author:

22

Matthew R. Allen

23

Dept of Anatomy & Cell Biology

24

635 Barnhill Drive, MS-5035

25

Indianapolis, IN 46202

26

Tel: (317) 274-1283

27

FAX: (317) 278-2040

28

Email: matallen@iupui.edu

This is the author's manuscript of the article published in final edited form as: Allen M. R., Burr D.B. (2009). The pathogenesis of biphosphonate-related osteonecrosis of the jaw: so many hypotheses, so few data. Journal of Oral and Maxillofacial Surgery, 67(5 Suppl): 61-70. Available from: <http://dx.doi.org/10.1016/j.joms.2009.01.007>

Abstract

Bisphosphonate-related osteonecrosis of the jaw (BRONJ) has generated great interest in the medical and research communities yet remains an enigma given its unknown pathogenesis. The goal of this review is to summarize the various proposed hypotheses underlying BRONJ. While a role of the oral mucosa has been proposed, the bone is likely the primary tissue of interest for BRONJ. The most popular BRONJ hypothesis, manifestation of necrotic bone resulting from bisphosphonate-induced remodeling suppression, is supported mostly by indirect evidence although recent data has shown bisphosphonates significantly reduce remodeling in the jaw. Remodeling suppression would be expected, and has been shown, to allow accumulation of non-viable osteocytes while a more direct cytotoxic effect of bisphosphonates on osteocytes has also been proposed. Bisphosphonates have anti-angiogenic effects, leading to speculation that this could contribute to the BRONJ pathogenesis. Compromised angiogenesis would most likely be involved in post-intervention healing although other aspects of the vasculature (e.g. blood flow) could contribute to BRONJ. Despite infection being present in many BRONJ patients, there is no clear evidence as to whether infection is a primary or secondary event in the pathophysiology. In addition to these main factors proposed in the pathogenesis, numerous co-factors associated with BRONJ (e.g. diabetes, smoking, dental extraction, concurrent medications), could interact with bisphosphonates and affect remodeling, angiogenesis/blood flow, and/or infection. As our lack of knowledge concerning BRONJ pathogenesis is due to a lack of data, it is only through the initiation of hypothesis-driven studies that significant progress will be made to understand this serious and debilitating condition.

Key words: Osteonecrosis of the jaw, bisphosphonates, bone remodeling, osteocytes, angiogenesis

Introduction

Bisphosphonate-related osteonecrosis of the jaw (BRONJ) has become one of the most prominent enigmas not only in the dental community, but in the field of skeletal biology as a whole. Confusion surrounding BRONJ exists for several reasons, including a lack of understanding about how and why this condition manifests¹. Since brought to light in 2003/2004²⁻⁵, well over 400 manuscripts have been published concerning BRONJ. Despite this large volume of work there remain few data, yet many hypotheses, concerning the underlying pathophysiology. The goal of this review is to summarize some of the various proposed hypotheses for the pathophysiology of BRONJ.

The starting point for BRONJ: Bone or soft tissue?

As its name implies, BRONJ is often assumed to be primarily a bone condition. The hallmark of BRONJ is the existence of exposed bone with the majority of cases manifesting following dental intervention¹. As epithelialization is an essential step in post-intervention wound healing^{6,7}, it has been hypothesized that the soft tissue of the oral mucosa could play a significant role in BRONJ. Specifically, it has been proposed that bisphosphonates, which accumulate in the bone, have direct toxic effects on the oral epithelium and inhibit normal healing of soft tissue lesions caused either by dental intervention or some other trauma^{8,9}. The failure of soft tissue to heal would result in exposure of the bone, which then becomes necrotic. Although dental extraction is a significant risk factor for BRONJ¹⁰, the condition does occur in the absence of dental intervention¹.

The effect of localized high concentration on the oral mucosa is most clearly illustrated by the case report of stomatitis in a patient who held their bisphosphonate medication in their mouth¹¹. However, use of bisphosphonates in gel form for treatment of periodontal lesions, although not widely studied and only used short-term, likely present the oral mucosa with high local concentrations and have not shown any adverse effects¹². Beyond this, however, little is known about bisphosphonates and the oral mucosa.

One key unknown for the hypothesis of soft-tissue toxicity is whether the oral mucosa, comprised of epithelial and vascular tissue, is exposed to sufficient bisphosphonate levels in vivo to disrupt its normal physiology. Since bisphosphonates only accumulate in the bone¹³, a scenario would most likely have to exist in which large amounts of drug are liberated either all at once, or at sufficiently high concentrations over a prolonged duration. It has been suggested that this would occur during dental intervention due to physical disruption of the bone^{8,9}, although this has not been assessed and would not explain the occurrence of BRONJ in the absence of dental procedures. Alternatively, sufficient concentrations of bisphosphonates in the saliva, or gingival crevicular fluid could expose the oral mucosa to high levels of drug. Whether or not the several BRONJ risk factors, such as diabetes, smoking, and concurrent medications, play a role in compromising the oral mucosa is also unclear. Thus, while the hypothesis remains intriguing and is worth further study, the skeleton seems most likely to serve as the central factor for initiation of BRONJ.

Bone cells and BRONJ: Where to focus attention

The physiological effects of bisphosphonates on bone cells - osteoblasts, osteoclasts, and osteocytes - have recently been expertly reviewed^{14,15}. Osteoclasts (**Figure 1a**) are the main cellular target of bisphosphonates¹⁶. Specifically, through disruption of intracellular pathways, bisphosphonates suppress osteoclast-mediated bone remodeling. As remodeling plays a vital role in tissue renewal and bone healing, bisphosphonate-induced remodeling suppression imparts significant effects on various tissue-level properties¹⁷⁻²². The effects of bisphosphonates on osteocytes (**Figure 1b**), the most abundant of the bone cells, are less clear and more controversial. Evidence exists for both direct and indirect effects, most of which are centered around the viability and integrity of these cells and their environment^{20,23-26}. Osteoblasts (**Figure 1c**) appear to be the least affected of the bone cells. . While systemic bone formation is reduced in the presence of bisphosphonates, this is primarily an indirect consequence of remodeling suppression and the coupling between resorption and formation. At the level of the individual basic multicellular unit osteoblast activity appears unaffected^{27,28}. Reports from small

animal models suggest that bisphosphonates may suppress osteoblastic bone formation directly on those surface undergoing bone formation without prior resorption (i.e .formation modeling)²⁹, although large animal models do not show a similar suppressive effect on periosteal surfaces³⁰⁻³². Collectively, this evidence points towards the osteoclasts and/or osteocytes as the main cells of interest for BRONJ pathogenesis.

Remodeling suppression and BRONJ: The basic premise of the most popular hypothesis

Nearly every report and review of BRONJ points to bisphosphonate-induced remodeling suppression as a likely mechanism. The basic premise of this hypothesis is that the jaw has a high remodeling rate and bisphosphonates suppress remodeling. There is no debate about the latter as this is the principal mechanism of action of the bisphosphonates^{14, 15}. It is also clear that remodeling, specifically within the intracortical envelope, is considerably higher in the jaw compared to other skeletal sites. As opposed to remodeling that occurs on bone surfaces, intracortical (osteonal) remodeling occurs within cortical bone of humans and many large animals³³. In humans, intracortical remodeling rates of the jaw are 10-20 times higher than within the cortex of the iliac crest^{34, 35}. Animal studies support the limited human data, consistently showing that remodeling rates in the jaw are significantly higher than in the long bones^{36, 37}. The BRONJ hypothesis thus follows the idea that since remodeling is high in the jaw, and bisphosphonates suppress remodeling, this likely plays a role in the pathophysiology of BRONJ.

Bisphosphonate effects on intracortical bone remodeling of the mandible have only recently been documented²⁰. Following three years of daily treatment with doses of oral alendronate that were either equivalent to the clinical dose for osteoporosis, or 5x higher, the level of intracortical remodeling was histologically assessed in skeletally mature beagle dogs. Consistent with previous work by others, untreated animals had mandible remodeling rates, specifically within the alveolar region, that were >10-fold higher than within long bones. Daily oral alendronate significantly suppressed intracortical bone formation rate of the mandible compared to vehicle, mainly due to suppression in the alveolar bone region (**Figure 2**)²⁰. These data represent clear evidence of bisphosphonate-induced turnover suppression in the jaw and

although consistent with both components of the remodeling-suppression hypothesis for BRONJ they do not establish a clear cause-effect relationship.

The incidence of BRONJ is significantly higher in cancer patients compared to those treated for osteoporosis¹ suggesting differences should exist in the degree of remodeling suppression between these two populations. Compared to treatment regimens used for osteoporosis, treatment regimens in cancer patients use bisphosphonates with higher potency and binding affinity (zoledronate and pamidronate) and involve both higher doses and more frequent dosing schedules. Differences in potencies and binding affinities among the bisphosphonates are known to affect the degree of remodeling suppression¹⁴, and both treatment dose and duration are associated with BRONJ^{10, 38-40}. Thus, it is reasonable to hypothesize that cancer patients may experience a greater remodeling suppression within the jaw, although such measurements have never been made even in pre-clinical models.

If remodeling suppression is part of the pathophysiology of BRONJ, one might expect it to occur during the course of treatment with other anti-catabolic therapies. Although no BRONJ cases have been reported in patients treated with other anti-remodeling agents (hormone replacement therapy, selective estrogen receptor modulators, and calcitonin), these agents typically do not suppress turnover by more than 50%. Denosumab, a monoclonal anti-RANKL antibody currently in clinical trials for both osteoporosis and cancer populations, has been shown to suppress remodeling an equal or greater extent than bisphosphonates^{41, 42}. Although no cases of BRONJ have been reported in patients treated with denosumab, increases in the number of treated patients, as well as the duration of treatment, will help to answer questions surrounding the role of remodeling suppression in BRONJ.

Individuals with genetic mutations affecting osteoclast activity provide a means of studying the effects of significant levels of remodeling suppression⁴³. Several of these genetic conditions have been reported to produce BRONJ-like symptoms^{44, 45}, supporting the idea of remodeling-suppression in the pathophysiology. For example, patients with inactivating mutations in the chloride channel 7 gene have autosomal dominant osteopetrosis (ADO), a condition in which osteoclast resorption is significantly compromised^{45, 46}. Jaw osteomyelitis was

noted in 13% of patients with ADO, compared to a complete absence of osteomyelitis in the control population⁴⁶. Interestingly, 5 of the ADO patients (8%) had draining fistulas and/or obvious bony destruction resulting in visible defects in the jaw or palate, a similar clinical presentation to that of BRONJ⁴⁷. Patients with a different genetic condition, pyknodysostosis, an autosomal recessive mutation in the cathepsin-K gene which inhibits osteoclast activity, have also been shown to develop exposed bone in the oral cavity^{48, 49}.

Perhaps the most intriguing reports supporting the remodeling suppression hypothesis of BRONJ concern resolution of the condition subsequent to treatment with agents that stimulate remodeling. In three separate case reports, patients with confirmed BRONJ were treated with teriparatide (recombinant human parathyroid hormone (1-34)), an FDA approved agent for treating post-menopausal osteoporosis which acts through stimulation of bone remodeling⁵⁰⁻⁵². While each of these cases involved numerous other interventions (including cessation of bisphosphonate treatment, debridement, and anti-bacterial washes), the resolution of BRONJ came only after introduction of teriparatide treatment.

The strongest challenge to the remodeling suppression hypothesis comes from children with osteogenesis imperfecta. These patients are routinely treated with high doses of bisphosphonates and to date there have been no reports of BRONJ^{53, 54}. It is unclear if or why bisphosphonates differentially affect remodeling in the jaw of young and old subjects.

An important aspect of the remodeling suppression hypothesis is that much of the focus has been on the pre-existing bone which may not be the true site of interest. Similar to fracture healing, after dental extraction the socket fills with woven bone which over time is remodeled into lamellar bone^{6, 7, 55}. The fracture healing literature clearly shows woven bone formation is not compromised in the presence of bisphosphonates, yet remodeling of this callus is significantly delayed^{22, 56-58}. Thus, it may be that bone formed early during oral wound healing is not remodeled in a timely fashion and this in turn develops into BRONJ. Although some investigation has occurred looking at extractions in the presence of bisphosphonates^{59, 60}, these studies have focused on the preservation of the alveolar bone structure. There exist no data to describe how bisphosphonates affect bone that is formed post-extraction or how it is remodeled over time.

The hypothesis of remodeling suppression as a factor in the pathophysiology of BRONJ makes sense and is supported by some data. Yet a key unanswered question is how the suppression of remodeling, even at a site with high turnover, results in necrotic bone and why this seems specific to the high doses of intravenous bisphosphonates.

Remodeling suppression and BRONJ: Focus on the osteocyte

There exists limited histological assessment of BRONJ tissue, yet that which exists almost universally notes the presence of empty lacunae – void of their resident osteocytes. Osteocytes, the most abundant bone cells, form an intricate communication network throughout the mineralized matrix (**Figure 3**) and play a key role in skeletal physiology^{61, 62}. While generally considered a long-lived cell, the lifespan of the osteocyte is finite and therefore over time these cells undergo natural death⁶³⁻⁶⁵. Under normal physiological conditions, loss of osteocytes and the associated changes to tissue can likely be held in check by bone remodeling⁶⁴. Yet as bisphosphonates suppress remodeling, regions of non-viable osteocytes would be expected to accumulate.

Focal loss of viable bone matrix has been documented in a pre-clinical animal model. Following three years of treatment with oral bisphosphonates, mandibles of beagle dogs contained significant regions of non-viable bone matrix²⁰. Using en bloc basic fuchsin staining which fills all voids within the matrix (microdamage, Haversian canals, osteocyte lacunae and canaliculi^{66, 67}), regions of non-viable bone matrix were identified by the absence of stain suggesting the osteocyte network had filled with mineral (**Figure 4**). Non-viable matrix was noted in a fraction of bisphosphonate-treated animals (~30%), most often in the alveolar portion of the bone, yet was not observed in any control animals²⁰. Using this same basic fuchsin technique, regions of matrix necrosis can be observed in pathological samples from BRONJ patients (**Figure 5**). Previous studies on samples from patients with BRONJ, using more standard methods of histological evaluation with hematoxylin and eosin staining, have also observed areas of bone tissue with empty lacuna interspersed among areas of vital bone⁶⁸. Although it remains unclear if

or how these areas of focal matrix necrosis play into BRONJ⁶⁹ these findings suggest the osteocyte could have a central role in the pathophysiology.

The accumulation of non-viable osteocytes in association with bisphosphonate treatment could manifest through indirect or direct mechanisms. As outlined above, osteocyte death is a natural process and through suppression of remodeling it would be expected that regions with non-viable cells would be more prevalent. This accumulation would have little to do with bisphosphonates, per se, but rather would be a result of suppressed remodeling. If this hypothesis is correct, it would be expected that other anti-remodeling agents, or other conditions which result in remodeling suppression, would also result in an accumulation of non-viable bone, and that it would be dose- or potency-dependent. Additionally, it would be expected that regions of non-viable bone would not be confined to the mandible but would be present throughout the skeleton.

An alternate hypothesis for the accumulation of non-viable osteocytes with bisphosphonates is through a direct effect of these drugs on the osteocytes^{9,69}. It is well accepted that bisphosphonates become embedded in the skeleton and therefore accumulate over time^{70,71}. It has recently been demonstrated that systemically administered bisphosphonates have access to, and become embedded in, the osteocyte lacunae⁷². As such, it is possible that osteocytes could be exposed to high concentrations of bisphosphonates over time which in turn could affect cell viability.

The effects of bisphosphonates on osteoblast/osteocyte viability have been predominantly investigated in vitro. Through connexin (Cx)-43 hemichannel transduction of extracellular signal regulated kinases (ERKs), low concentrations of bisphosphonates have been shown to suppress osteocyte apoptosis through maintenance of cellular connections^{26, 73-75}. These results have translated well to in vivo models where bisphosphonates have also been shown to suppress prednisone-induced²⁶ and mechanically-induced²⁵ osteocyte apoptosis. However, the anti-apoptotic effects in vitro appear to be dose-dependent such that higher concentrations increase osteocyte apoptosis²⁴. This establishes a plausible scenario where osteocytes are initially exposed to low levels of bisphosphonates which prolong osteocyte

longevity yet with continued treatment, particularly at high doses, concentrations of drug accumulate near the osteocyte which results in cell death.

Whether these direct or indirect pathways connecting bisphosphonates to loss of osteocyte viability play a role in BRONJ is unclear. Of the two, the direct pathway is more consistent with numerous clinical aspects of the condition. BRONJ is more prominent in patients treated with high-doses of intravenous pamidronate or zoledronate, as compared to those treated at lower doses for osteoporosis¹. Intravenous administration results in a higher skeletal accumulation as compared to oral administration¹³, while pamidronate and zoledronate have the highest mineral binding affinities among all of the bisphosphonates^{76, 77}. The increased risk of BRONJ associated with treatment duration is also consistent with the accumulation of drug over time.

Given the central role of osteocytes in the regulation of the skeleton, understanding how pharmacological agents affect their physiology is essential. The effects of bisphosphonates on osteocytes are only now beginning to be understood. Despite indirect evidence that the loss of osteocyte viability could play a role in the pathophysiology of BRONJ, the paucity of data results in this remaining a hypothesis.

BRONJ and vasculature: The anti-angiogenic effects of bisphosphonates.

Prior to the emergence of BRONJ, much of what was known concerning osteonecrosis centered on two conditions which manifest due to disruptions in vasculature. Avascular necrosis of the hip occurs secondary to disruption of the vasculature⁷⁸. Similarly, osteoradionecrosis, most prominently of the jaw, occurs following radiation-induced disruption of the vasculature^{68, 79, 80}. The existence of these conditions, and the clear role of disrupted vasculature in their pathophysiology, has led to the hypothesis that the vasculature plays a key role in pathophysiology of BRONJ.

A role of the vasculature in BRONJ has been mostly fueled by studies showing anti-angiogenic properties of bisphosphonates. Indeed, bisphosphonates are emerging as a potential means of suppressing angiogenesis associated with tumor growth^{81, 82}. Numerous studies have

documented anti-angiogenic effects of bisphosphonates in vitro while a smaller number have shown similar effects in vivo. The latter include suppression of angiogenesis in subcutaneously implanted tissue chambers⁸³, reduced testosterone-induced prostate tissue re-vascularization following castration⁸⁴, and significant reductions in marrow vessel number of iliac crest biopsies after six months of clodronate treatment for Paget's disease⁸⁴. Conversely, early in vivo studies with high doses of bisphosphonates did not document altered vascular invasion near the growth plates⁸⁵. There have been no systematic studies assessing the vascular pattern in BRONJ. Qualitatively, the vasculature has been reported to be intact in a series of BRONJ cases⁸⁶ while a separate series reported 'vessel obliteration' in some BRONJ specimens^{68, 87}. In the dog model of matrix necrosis the vasculature appears to be patent and intact even in regions devoid of viable osteocytes²⁰.

Recently, two cases of exposed bone in the mandible, similar in nature to BRONJ, have been reported in cancer patients treated with Bevacizumab, a recombinant human monoclonal antibody that binds to vascular endothelial growth factor (VEGF) and inhibits angiogenesis⁸⁸. These patients were not treated with bisphosphonates and did not undergo any dental intervention. This provides the strongest evidence to date suggesting a role of the vasculature in BRONJ.

Reduced angiogenesis within bone would actually be expected to occur with bisphosphonates, due to a suppression of remodeling. Each remodeling unit receives its nutrients by a vessel⁸⁹; therefore bone remodeling and angiogenesis are intimately linked. Bisphosphonate-induced reductions in remodeling should be associated with reduced angiogenesis yet the reduction would be a secondary effect. It remains unclear if this has relevance to BRONJ.

Perhaps the most intriguing role of altered angiogenesis with bisphosphonates may be related to wound healing⁹⁰. Following tooth extraction, a major precipitating event in BRONJ¹⁰, the extraction site undergoes a well-defined series of healing steps which include an initial clot formation, conversion of clot to granulation tissue, formation of connective tissue and pre-osseous tissue, and finally filling of the extraction socket with bone^{7, 91-93}. Disruption of this

normal process at any stage, particularly the formation of the provisional matrix that occurs early during treatment, could compromise the entire process⁹⁰. Furthermore, disruption of the remodeling of this extraction site by osteoclasts, which normally occurs via an accelerated rate of modeling and remodeling^{55, 93}, may potentially play into the lack of healing that is a prominent feature of BRONJ. The sole evidence on this topic comes from an in vivo study in mice which showed that bisphosphonates did not affect angiogenesis associated with endochondral ossification, a process that is similar to that which occurs with skeletal wound healing⁹⁴.

Another aspect related to vasculature, but not as routinely discussed in the BRONJ literature as angiogenesis, is potential effects of bisphosphonates on blood flow⁹⁰. Tissue blood flow is directly proportional to its metabolic activity with the bone receiving ~4-7% of total cardiac output at rest⁹⁵ compared to ~17% for skeletal muscle⁹⁶. Blood flow distribution throughout the skeleton is heterogeneous and varies by a factor of ten among bones⁹⁷. Given its high remodeling rate, the mandible would be expected to have high blood flow rates. The lone data concerning mandible blood flow show values for the mandible that are similar to long bones^{97, 98}. Importantly, however, these flow rates in the mandible are probably underestimated as the teeth likely account for a significant portion of the mass, yet do not directly receive blood. Regardless of basal blood flow, it would be expected that blood flow to the mandible would be reduced with bisphosphonates due to the suppression of remodeling (which would lower the metabolic demand). This reduced blood flow would lead to vascular remodeling⁹⁹ with the skeletal vessels becoming smaller and thus less able to accommodate the demands for skeletal perfusion that are known to exist post-extraction or with infection^{100, 101}. The inability to raise blood flow in these circumstances could compromise tissue viability and play a role in BRONJ.

BRONJ and Infection: It's there but does it contribute to the pathophysiology

Numerous bacteria have been reported in patients with BRONJ yet there is nearly a universal presence of *Actinomyces*^{68, 86, 87 102}. *Actinomyces* species, most commonly *Actinomyces israelii*, are the most prominent of the over 500 microflora in the oral cavity¹⁰³. Through their formation of a biofilm on the bone/tooth/mucosal surface, *Actinomyces* perpetuate the adherence of other

microflora which results in a heterogeneous population of bacteria primed for development of infection¹⁰³. Despite the presence of these bacterial conglomerates in many patients with BRONJ, there is no clear evidence to address the question of whether infection is a primary or secondary event in BRONJ pathophysiology.

One plausible mechanism through which infection could contribute to BRONJ is by enhancing osteoclast-independent bone resorption. BRONJ tissue consistently shows a prevalence of scalloped bone surfaces^{68, 86, 87} (**Figure 5**), a seemingly paradoxical property given the effect of bisphosphonates on bone resorption. Bacteria and associated fibroblast-like cells have the capacity to directly resorb bone, independent of osteoclasts, by liberating various acids and proteases^{102, 104, 105}. As osteoclasts signal osteoblasts during normal bone remodeling^{106, 107}, resorption that occurs independent of osteoclasts would likely lack osteoblast-mediated bone formation. Whether such resorption could factor into BRONJ is unclear but seems worth exploring.

Other hypotheses of BRONJ

In addition to the hypotheses outlined above, numerous others exist mostly related to the role of various co-factors in the pathophysiology of BRONJ. Co-morbidities (e.g. diabetes¹⁰⁸), lifestyle factors (e.g. smoking¹⁰⁹ and obesity¹⁰⁹), interventions (e.g. dental extraction¹⁰), and concurrent medications (e.g. corticosteroids⁽¹¹⁰⁾) have all been associated with BRONJ. With all of these factors, the proposed mechanism for contribution to BRONJ relates back to the main mechanisms outlined above – remodeling, angiogenesis/blood flow, and infection. As dental manifestations similar to BRONJ have not been observed with any of these co-factors in the absence of bisphosphonates, it suggests either these co-factors don't play a significant role or that it is the interaction between the co-factors and bisphosphonates that is the key to the pathophysiology.

Future Directions: Data anyone?

Above all else, the field of BRONJ needs data. The amount of data, excluding those concerning incidence/prevalence/risk factors, is appalling given the five years that have passed since the initial descriptions of this condition. Without undertaking hypothesis-driven studies to tease apart the potential pathophysiology we simply won't get any closer to understanding this condition. Recently, the American Society for Bone and Mineral Research organized a multi-disciplinary task force concerning BRONJ which put forward several questions/areas of study, ranging from clinical to molecular, that the field needs to advance ¹. While this provides an excellent starting point, the topics outlined are not all encompassing; other important areas related to BRONJ surely exist. The key is that we need to start generating data, without which interest in BRONJ within the research community will wane as the field will simply not move forward. We are dangerously close to this happening and for the sake of the patients with BRONJ we must do everything we can to understand all that we can.

Figure Legends

Figure 1. The pathophysiology of BRONJ likely involves one or more of the bone cell populations. Osteoclasts (A), seen here stained with tartrate-resistant acid phosphatase, function to resorb bone; suppression of their activity is the mechanism underlying the effectiveness of bisphosphonate treatment. Osteocytes (B), entombed within the mineralized matrix, are connected to each other and to the bone surface by an intricate cell process network (seen here stained with basic fuchsin); the effect of bisphosphonates on these cells remains controversial. Osteoblasts (C), seen here as tall cuboidal cells actively forming osteoid (the thin pale blue seam adjacent to the bone surface), are less active in the presence of bisphosphonates although this is predominately an indirect effect of reduced bone remodeling. Scale bars = 50 µm.

Figure 2. Bisphosphonates reduce mandible bone remodeling. Following three years of daily treatment with oral alendronate (ALN), at the dose used for osteoporosis treatment (ALN

0.2) or a dose 5x higher (ALN1.0), intracortical bone formation rate was assessed in the mandible of female beagle dogs. There was a significant reduction in the overall bone formation rate of the mandible with both doses of alendronate compared to age-matched animals treated with vehicle. The greatest suppression of turnover was noted in the alveolar portion of the mandible with no significant effect of ALN treatment on turnover suppression in the non-alveolar portion. $*p < 0.05$ versus VEH. Adapted from *J Oral Maxillofac Surg*, 66(5), MR Allen and DB Burr, *Mandible Matrix Necrosis in Beagle Dogs After 3 Years of Daily Oral Bisphosphonate Treatment*, 2008, with permission from Elsevier.

Figure 3. The osteocyte lacunar-canalicular network. Using acid etching of plastic embedded specimens, the intricate nature of the lacunar-canalicular system can be revealed. Disruption of this network could play a significant role in the pathophysiology of BRONJ. Scale bar = 50 μ m. Image complements of Daniel Kubek, Indiana University School of Medicine.

Figure 4. Mandible matrix necrosis following bisphosphonate treatment in a pre-clinical model. Following three years of daily treatment with alendronate (ALN), regions of focal matrix necrosis existed in the mandibles of beagle dogs. Using en bloc basic fuchsin staining, which passively diffuses and fills all void spaces (blood vessels, lacunae, canaliculi), viable bone matrix tissue can easily be identified by the presence of stain; the absence of stain indicates the lack of permeability to a given region. In this representative photomicrograph of a mandible from an ALN-treated animal, the central region is noticeably void of stain and therefore considered to be non-viable tissue. Peripheral to the central region of non-viable bone matrix, tissue that is sufficiently stained (and therefore considered viable) can be observed. The upper right of the photomicrograph shows the tooth, below which is the periodontal ligament (which is heavily stained with fuchsin). Scale bar = 500 μ m.

Figure 5. Non-viable bone matrix in BRONJ specimens. Using en bloc basic fuchsin staining, regions of non-viable bone matrix can be observed in a pathological specimen from a patient with BRONJ (courtesy of Dr. Salvatore Ruggiero). Similar to that observed in bisphosphonate-treated beagle dogs, a region void of fuchsin stain, and therefore considered non-viable, is surrounded by stained (viable) tissue. Scale bar = 100 μ m.

Figure 6. Extensive scalloped bone surfaces in BRONJ tissue. Using high-resolution micro-computed tomography (Skyscan 1172, 5 μ m resolution), the extent of eroded surfaces (examples shown by arrows) in a sequestrum from a patient with BRONJ (courtesy of Dr. Salvatore Ruggiero) can be visualized. Such extensive erosion would be unexpected in patients treated with bisphosphonates, suggesting osteoclast-independent mechanisms of bone resorption may be active in BRONJ. Scale bar = 1 mm.

References

1. Khosla, S., D. Burr, J. Cauley, et al. Bisphosphonate-associated osteonecrosis of the jaw: report of a task force of the American Society for Bone and Mineral Research. *J Bone Miner Res.* 22(10): 1479-91. 2007.
2. Marx, R.E. Pamidronate (Aredia) and zoledronate (Zometa) induced avascular necrosis of the jaws: a growing epidemic. *J Oral Maxillofac Surg.* 61(9): 1115-7. 2003.
3. Mehrotra, B., J. Fantasia, S. Nissel-Horowitz, et al. Osteonecrosis of the maxilla: an unusual complication of prolonged bisphosphonate therapy. a case report. . *Proc Am Soc Clin Oncol.* 22: (abstr 3194). 2003.
4. Ruggiero, S.L., B. Mehrotra, T.J. Rosenberg, et al. Osteonecrosis of the jaws associated with the use of bisphosphonates: a review of 63 cases. *J Oral Maxillofac Surg.* 62(5): 527-34. 2004.
5. Wang, J., N.M. Goodger, and M.A. Pogrel. Osteonecrosis of the jaws associated with cancer chemotherapy. *J Oral Maxillofac Surg.* 61(9): 1104-7. 2003.
6. Amler, M.H., P.L. Johnson, and I. Salman. Histological and histochemical investigation of human alveolar socket healing in undisturbed extraction wounds. *J Am Dent Assoc.* 61: 32-44. 1960.
7. Cardaropoli, G., M. Araujo, and J. Lindhe. Dynamics of bone tissue formation in tooth extraction sites. An experimental study in dogs. *J Clin Periodontol.* 30(9): 809-18. 2003.
8. Reid, I.R., M.J. Bolland, and A.B. Grey. Is bisphosphonate-associated osteonecrosis of the jaw caused by soft tissue toxicity? *Bone.* 41(3): 318-20. 2007.
9. Reid, I.R. and T. Cundy. Osteonecrosis of the jaw. *Skeletal Radiol.* 2008.
10. Mavrokokki, T., A. Cheng, B. Stein, et al. Nature and frequency of bisphosphonate-associated osteonecrosis of the jaws in Australia. *J Oral Maxillofac Surg.* 65(3): 415-23. 2007.
11. Rubegni, P. and M. Fimiani. Images in clinical medicine. Bisphosphonate-associated contact stomatitis. *N Engl J Med.* 355(22): e25. 2006.

- 454 12. Reddy, G.T., T.M. Kumar, and Veena. Formulation and evaluation of Alendronate
455 Sodium gel for the treatment of bone resorptive lesions in Periodontitis. *Drug Deliv.* 12(4):
456 217-22. 2005.
- 457 13. Lin, J.H. Bisphosphonates: a review of their pharmacokinetic properties. *Bone.* 18(2): 75-
458 85. 1996.
- 459 14. Russell, R.G., N.B. Watts, F.H. Ebetino, et al. Mechanisms of action of bisphosphonates:
460 similarities and differences and their potential influence on clinical efficacy. *Osteoporos*
461 *Int.* 2008.
- 462 15. Russell, R.G., Z. Xia, J.E. Dunford, et al. Bisphosphonates: an update on mechanisms of
463 action and how these relate to clinical efficacy. *Ann N Y Acad Sci.* 1117: 209-57. 2007.
- 464 16. Rodan, G.A. and H.A. Fleisch. Bisphosphonates: mechanisms of action. *J Clin Invest.*
465 97(12): 2692-6. 1996.
- 466 17. Allen, M.R., K. Iwata, R. Phipps, et al. Alterations in canine vertebral bone turnover,
467 microdamage accumulation, and biomechanical properties following 1-year treatment
468 with clinical treatment doses of risedronate or alendronate. *Bone.* 39(4): 872-9. 2006.
- 469 18. Mashiba, T., C.H. Turner, T. Hirano, et al. Effects of suppressed bone turnover by
470 bisphosphonates on microdamage accumulation and biomechanical properties in
471 clinically relevant skeletal sites in beagles. *Bone.* 28(5): 524-31. 2001.
- 472 19. Allen, M.R. and D.B. Burr. Three years of alendronate treatment results in similar levels
473 of vertebral microdamage as after one year of treatment. *J Bone Miner Res.* 22(11):
474 1759-65. 2007.
- 475 20. Allen, M.R. and D.B. Burr. Mandible matrix necrosis in beagle dogs after 3 years of daily
476 oral bisphosphonate treatment. *J Oral Maxillofac Surg.* 66(5): 987-94. 2008.
- 477 21. Boivin, G.Y., P.M. Chavassieux, A.C. Santora, et al. Alendronate increases bone strength
478 by increasing the mean degree of mineralization of bone tissue in osteoporotic women.
479 *Bone.* 27(5): 687-94. 2000.
- 480 22. McDonald, M.M., S. Dulai, C. Godfrey, et al. Bolus or weekly zoledronic acid
481 administration does not delay endochondral fracture repair but weekly dosing enhances
482 delays in hard callus remodeling. *Bone.* 2008.
- 483 23. Plotkin, L.I., J.I. Aguirre, S. Kousteni, et al. Bisphosphonates and estrogens inhibit
484 osteocyte apoptosis via distinct molecular mechanisms downstream of extracellular
485 signal-regulated kinase activation. *J Biol Chem.* 280(8): 7317-25. 2005.
- 486 24. Idris, A.I., J. Rojas, I.R. Greig, et al. Aminobisphosphonates cause osteoblast apoptosis
487 and inhibit bone nodule formation in vitro. *Calcif Tissue Int.* 82(3): 191-201. 2008.
- 488 25. Follet, H., J. Li, R.J. Phipps, et al. Risedronate and alendronate suppress osteocyte
489 apoptosis following cyclic fatigue loading. *Bone.* 40(4): 1172-7. 2007.
- 490 26. Plotkin, L.I., R.S. Weinstein, A.M. Parfitt, et al. Prevention of osteocyte and osteoblast
491 apoptosis by bisphosphonates and calcitonin. *J Clin Invest.* 104(10): 1363-74. 1999.
- 492 27. Boyce, R.W., C.L. Paddock, J.R. Gleason, et al. The effects of risedronate on canine
493 cancellous bone remodeling: three-dimensional kinetic reconstruction of the remodeling
494 site. *J Bone Miner Res.* 10(2): 211-21. 1995.
- 495 28. Eriksen, E.F., F. Melsen, E. Sod, et al. Effects of long-term risedronate on bone quality
496 and bone turnover in women with postmenopausal osteoporosis. *Bone.* 31(5): 620-5.
497 2002.
- 498 29. Iwata, K., J. Li, H. Follet, et al. Bisphosphonates suppress periosteal osteoblast activity
499 independent of resorption in rat femur and tibia. *Bone.* 39(5): 1053-8. 2006.
- 500 30. Allen, M.R., H. Follet, M. Khurana, et al. Anti-remodeling agents influence osteoblast
501 activity differently in modeling- and remodeling-associated bone formation *Calcified*
502 *Tissue International.* 79(4): 255-61. 2006.
- 503 31. Allen, M.R., S. Reinwald, and D.B. Burr. Alendronate reduces bone toughness of ribs
504 without significantly increasing microdamage accumulation in dogs following 3 years of
505 daily treatment. *Calcif Tissue Int.* 82(5): 354-60. 2008.
- 506 32. Mashiba, T., T. Hirano, C.H. Turner, et al. Suppressed bone turnover by
507 bisphosphonates increases microdamage accumulation and reduces some
508 biomechanical properties in dog rib. *J Bone Miner Res.* 15(4): 613-20. 2000.

- 509 33. Reinwald, S. and D. Burr. Review of nonprimate, large animal models for osteoporosis
510 research. *J Bone Miner Res.* 23(9): 1353-68. 2008.
- 511 34. Garetto, L.P., J. Chen, J.A. Parr, et al. Remodeling dynamics of bone supporting rigidly
512 fixed titanium implants: a histomorphometric comparison in four species including
513 humans. *Implant Dent.* 4(4): 235-43. 1995.
- 514 35. Han, Z.H., S. Palnitkar, D.S. Rao, et al. Effects of ethnicity and age or menopause on the
515 remodeling and turnover of iliac bone: implications for mechanisms of bone loss. *J Bone*
516 *Miner Res.* 12(4): 498-508. 1997.
- 517 36. Huja, S.S., S.A. Fernandez, K.J. Hill, et al. Remodeling dynamics in the alveolar process
518 in skeletally mature dogs. *Anat Rec A Discov Mol Cell Evol Biol.* 288(12): 1243-9. 2006.
- 519 37. Garetto, L.P. and N.D. Tricker. 1998 Remodeling of bone surrounding the implant
520 interface., in *Bridging the Gap Between Dental & Orthopaedic Implants*, 3rd Annual
521 Indiana Conference, L.P. Garetto, et al., Editors: Indianapolis, IN.
- 522 38. Bamias, A., E. Kastritis, C. Bamia, et al. Osteonecrosis of the jaw in cancer after
523 treatment with bisphosphonates: incidence and risk factors. *J Clin Oncol.* 23(34): 8580-7.
524 2005.
- 525 39. Dimopoulos, M.A., E. Kastritis, A. Anagnostopoulos, et al. Osteonecrosis of the jaw in
526 patients with multiple myeloma treated with bisphosphonates: evidence of increased risk
527 after treatment with zoledronic acid. *Haematologica.* 91(7): 968-71. 2006.
- 528 40. Corso, A., M. Varettoni, P. Zappasodi, et al. A different schedule of zoledronic acid can
529 reduce the risk of the osteonecrosis of the jaw in patients with multiple myeloma.
530 *Leukemia.* 2007.
- 531 41. Lewiecki, E.M., P.D. Miller, M.R. McClung, et al. Two-year treatment with denosumab
532 (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD. *J*
533 *Bone Miner Res.* 22(12): 1832-41. 2007.
- 534 42. Lipton, A., G.G. Steger, J. Figueroa, et al. Randomized active-controlled phase II study of
535 denosumab efficacy and safety in patients with breast cancer-related bone metastases. *J*
536 *Clin Oncol.* 25(28): 4431-7. 2007.
- 537 43. Helfrich, M.H. Osteoclast diseases and dental abnormalities. *Arch Oral Biol.* 50(2): 115-
538 22. 2005.
- 539 44. Barry, C.P., C.D. Ryan, and L.F. Stassen. Osteomyelitis of the maxilla secondary to
540 osteopetrosis: a report of 2 cases in sisters. *J Oral Maxillofac Surg.* 65(1): 144-7. 2007.
- 541 45. Johnston, C.C., Jr., N. Lavy, T. Lord, et al. Osteopetrosis. A clinical, genetic, metabolic,
542 and morphologic study of the dominantly inherited, benign form. *Medicine (Baltimore).*
543 47(2): 149-67. 1968.
- 544 46. Waguespack, S.G., D.L. Koller, K.E. White, et al. Chloride channel 7 (CLCN7) gene
545 mutations and autosomal dominant osteopetrosis, type II. *J Bone Miner Res.* 18(8): 1513-
546 8. 2003.
- 547 47. Ruggiero, S.L. and S.J. Drew. Osteonecrosis of the jaws and bisphosphonate therapy. *J*
548 *Dent Res.* 86(11): 1013-21. 2007.
- 549 48. Bathi, R.J. and V.N. Masur. Pyknodysostosis--a report of two cases with a brief review of
550 the literature. *Int J Oral Maxillofac Surg.* 29(6): 439-42. 2000.
- 551 49. Dimitrakopoulos, I., C. Magopoulos, and T. Katopodi. Mandibular osteomyelitis in a
552 patient with pyknodysostosis: a case report of a 50-year misdiagnosis. *J Oral Maxillofac*
553 *Surg.* 65(3): 580-5. 2007.
- 554 50. Harper, R.P. and E. Fung. Resolution of bisphosphonate-associated osteonecrosis of the
555 mandible: possible application for intermittent low-dose parathyroid hormone [rhPTH(1-
556 34)]. *J Oral Maxillofac Surg.* 65(3): 573-80. 2007.
- 557 51. Lau, A.N., S.H. Ali, and J.D. Adachi. Resolution of osteonecrosis of the jaw after
558 teriparatide [recombinant human PTH (1-34)] therapy. *Osteoporos Int.* 19 (Suppl 1): S80.
559 2008.
- 560 52. Wang, H.L., D. Weber, and L.K. McCauley. Effect of long-term oral bisphosphonates on
561 implant wound healing: literature review and a case report. *J Periodontol.* 78(3): 584-94.
562 2007.

53. Malmgren, B., E. Astrom, and S. Soderhall. No osteonecrosis in jaws of young patients with osteogenesis imperfecta treated with bisphosphonates. *J Oral Pathol Med.* 37(4): 196-200. 2008.
54. Schwartz, S., C. Joseph, D. Iera, et al. Bisphosphonates, osteonecrosis, osteogenesis imperfecta and dental extractions: a case series. *J Can Dent Assoc.* 74(6): 537-42. 2008.
55. Kingsmill, V.J. Post-extraction remodeling of the adult mandible. *Crit Rev Oral Biol Med.* 10(3): 384-404. 1999.
56. Li, C., S. Mori, J. Li, et al. Long-term effect of incadronate disodium (YM-175) on fracture healing of femoral shaft in growing rats. *J Bone Miner Res.* 16(3): 429-36. 2001.
57. Li, J., S. Mori, Y. Kaji, et al. Concentration of bisphosphonate (incadronate) in callus area and its effects on fracture healing in rats. *J Bone Miner Res.* 15(10): 2042-51. 2000.
58. Peter, C.P., W.O. Cook, D.M. Nunamaker, et al. Effect of alendronate on fracture healing and bone remodeling in dogs. *J Orthop Res.* 14(1): 74-9. 1996.
59. Altundal, H. and O. Guvener. The effect of alendronate on resorption of the alveolar bone following tooth extraction. *Int J Oral Maxillofac Surg.* 33(3): 286-93. 2004.
60. Olson, H.M. and A. Hagen. Inhibition of post-extraction alveolar ridge resorption in rats by dichloromethane diphosphonate. *J Periodontal Res.* 17(6): 669-74. 1982.
61. Bonewald, L.F. Osteocytes as dynamic multifunctional cells. *Ann N Y Acad Sci.* 1116: 281-90. 2007.
62. Turner, C.H., A.G. Robling, R.L. Duncan, et al. Do bone cells behave like a neuronal network? *Calcif Tissue Int.* 70(6): 435-42. 2002.
63. Weinstein, R.S., R.L. Jilka, A.M. Parfitt, et al. Inhibition of osteoblastogenesis and promotion of apoptosis of osteoblasts and osteocytes by glucocorticoids. Potential mechanisms of their deleterious effects on bone. *J Clin Invest.* 102(2): 274-82. 1998.
64. Enlow, D.H. Functions of the Haversian system. *Am J Anat.* 110: 269-305. 1962.
65. Frost, H.M. In vivo osteocyte death. *J Bone Joint Surg Am.* 42-A: 138-43. 1960.
66. Burr, D.B. and M. Hooser. Alterations to the en bloc basic fuchsin staining protocol for the demonstration of microdamage produced in vivo. *Bone.* 17(4): 431-3. 1995.
67. Frost, H.M. Micropetrosis. *J Bone Joint Surg Am.* 42-A: 144-50. 1960.
68. Hansen, T., M. Kunkel, A. Weber, et al. Osteonecrosis of the jaws in patients treated with bisphosphonates - histomorphologic analysis in comparison with infected osteoradionecrosis. *J Oral Pathol Med.* 35(3): 155-60. 2006.
69. Allen, M.R. Bisphosphonates and Osteonecrosis of the Jaw: Moving From the 'Bedside' to the 'Bench'. *Cells, Tissues, Organs.* In Press. 2008.
70. Masarachia, P., M. Weinreb, R. Balena, et al. Comparison of the distribution of 3H-alendronate and 3H-etidronate in rat and mouse bones. *Bone.* 19(3): 281-90. 1996.
71. Lin, J.H., D.E. Duggan, I.W. Chen, et al. Physiological disposition of alendronate, a potent anti-osteolytic bisphosphonate, in laboratory animals. *Drug Metab Dispos.* 19(5): 926-32. 1991.
72. Roelofs, A.J., F.P. Coxon, F.H. Ebetino, et al. Use of a fluorescent analogue of risedronate to study localization and cellular uptake of bisphosphonates in vivo. *Bone.* 42: S85. 2008.
73. Plotkin, L.I., S.C. Manolagas, and T. Bellido. Transduction of cell survival signals by connexin-43 hemichannels. *J Biol Chem.* 277(10): 8648-57. 2002.
74. Plotkin, L.I., S.C. Manolagas, and T. Bellido. Dissociation of the pro-apoptotic effects of bisphosphonates on osteoclasts from their anti-apoptotic effects on osteoblasts/osteocytes with novel analogs. *Bone.* 39(3): 443-52. 2006.
75. Plotkin, L.I., V. Lezcano, J. Thostenson, et al. Connexin 43 Is Required for the Anti-Apoptotic Effect of Bisphosphonates on Osteocytes and Osteoblasts In Vivo. *J Bone Miner Res.* 2008.
76. Nancollas, G.H., R. Tang, R.J. Phipps, et al. Novel insights into actions of bisphosphonates on bone: Differences in interactions with hydroxyapatite. *Bone.* 2005.
77. Leu, C.T., E. Luegmayer, L.P. Freedman, et al. Relative binding affinities of bisphosphonates for human bone and relationship to antiresorptive efficacy. *Bone.* 38(5): 628-36. 2006.

- 618 78. Kim, H.K. Introduction to osteonecrosis of the femoral head (OFH) and osteonecrosis of
619 the jaw (ONJ). *J Musculoskelet Neuronal Interact.* 7(4): 350-3. 2007.
- 620 79. Store, G. and M. Boysen. Mandibular osteoradionecrosis: clinical behaviour and
621 diagnostic aspects. *Clin. Otolaryngol.* 25: 378-384. 2000.
- 622 80. Store, G. and G. Grandstrom. Osteoradionecrosis of the mandible: a microradiographic
623 study of cortical bone. *Scan J Plast Reconstr Hand Surg.* 33: 307-314. 1999.
- 624 81. Guise, T.A. Antitumor effects of bisphosphonates: promising preclinical evidence. *Cancer*
625 *Treat Rev.* 34 Suppl 1: S19-24. 2008.
- 626 82. Lipton, A. Emerging role of bisphosphonates in the clinic--antitumor activity and
627 prevention of metastasis to bone. *Cancer Treat Rev.* 34 Suppl 1: S25-30. 2008.
- 628 83. Wood, J., K. Bonjean, S. Ruetz, et al. Novel antiangiogenic effects of the bisphosphonate
629 compound zoledronic acid. *J Pharmacol Exp Ther.* 302(3): 1055-61. 2002.
- 630 84. Fournier, P., S. Boissier, S. Filleur, et al. Bisphosphonates inhibit angiogenesis in vitro
631 and testosterone-stimulated vascular regrowth in the ventral prostate in castrated rats.
632 *Cancer Res.* 62(22): 6538-44. 2002.
- 633 85. Schenk, R., W.A. Merz, R. Muhlbauer, et al. Effect of ethane-1-hydroxy-1,1-
634 diphosphonate (EHDP) and dichloromethylene diphosphonate (Cl 2 MDP) on the
635 calcification and resorption of cartilage and bone in the tibial epiphysis and metaphysis of
636 rats. *Calcif Tissue Res.* 11(3): 196-214. 1973.
- 637 86. Hellstein, J.W. and C.L. Marek. Bisphosphonate osteochemonecrosis (bis-phossy jaw): is
638 this phossy jaw of the 21st century? *J Oral Maxillofac Surg.* 63(5): 682-9. 2005.
- 639 87. Hansen, T., M. Kunkel, E. Springer, et al. Actinomycosis of the jaws--histopathological
640 study of 45 patients shows significant involvement in bisphosphonate-associated
641 osteonecrosis and infected osteoradionecrosis. *Virchows Arch.* 451(6): 1009-17. 2007.
- 642 88. Estilo, C.L., M. Fornier, A. Farooki, et al. Osteonecrosis of the jaw related to
643 bevacizumab. *J Clin Oncol.* 26(24): 4037-8. 2008.
- 644 89. Parfitt, A.M. The mechanism of coupling: a role for the vasculature. *Bone.* 26(4): 319-23.
645 2000.
- 646 90. Somerman, M.J. and L.K. McCauley. Bisphosphonates: Sacrificing the jaw to save the
647 skeleton? *BoneKEY-Osteovision.* 3(9): 12-18. 2006.
- 648 91. Adeyemo, W.L., A.L. Ladeinde, and M.O. Ogunlewe. Clinical evaluation of post-extraction
649 site wound healing. *J Contemp Dent Pract.* 7(3): 40-9. 2006.
- 650 92. Amler, M.H. Disturbed healing of extraction wounds. *J Oral Implantol.* 25(3): 179-84.
651 1999.
- 652 93. Trombelli, L., R. Farina, A. Marzola, et al. Modeling and remodeling of human extraction
653 sockets. *J Clin Periodontol.* 35(7): 630-9. 2008.
- 654 94. Deckers, M.M., E.R. Van Beek, G. Van Der Pluijm, et al. Dissociation of angiogenesis
655 and osteoclastogenesis during endochondral bone formation in neonatal mice. *J Bone*
656 *Miner Res.* 17(6): 998-1007. 2002.
- 657 95. Tothill, P. and J.N. MacPherson. The distribution of blood flow to the whole skeleton in
658 dogs, rabbits and rats measured with microspheres. *Clin Phys Physiol Meas.* 7(2): 117-
659 23. 1986.
- 660 96. Rowell, L.B. 1993 *Human Cardiovascular Control.* New York: Oxford University Press.
- 661 97. Colleran, P.N., M.K. Wilkerson, S.A. Bloomfield, et al. Alterations in skeletal perfusion
662 with simulated microgravity: a possible mechanism for bone remodeling. *J Appl Physiol.*
663 89(3): 1046-54. 2000.
- 664 98. Bloomfield, S.A., H.A. Hogan, and M.D. Delp. Decreases in bone blood flow and bone
665 material properties in aging Fischer-344 rats. *Clin Orthop Relat Res.* (396): 248-57. 2002.
- 666 99. Delp, M.D., P.N. Colleran, M.K. Wilkerson, et al. Structural and functional remodeling of
667 skeletal muscle microvasculature is induced by simulated microgravity. *Am J Physiol*
668 *Heart Circ Physiol.* 278(6): H1866-73. 2000.
- 669 100. Lurie, A.G. and S.R. Matteson. 99mTc-diphosphonate bone imaging and uptake in
670 healing rat extraction sockets. *J Nucl Med.* 17(8): 688-92. 1976.
- 671 101. McDougall, I.R. Skeletal scintigraphy. *West J Med.* 130(6): 503-14. 1979.

- 672 102. Sedghizadeh, P.P., S.K. Kumar, A. Gorur, et al. Identification of microbial biofilms in
673 osteonecrosis of the jaws secondary to bisphosphonate therapy. *J Oral Maxillofac Surg.*
674 66(4): 767-75. 2008.
- 675 103. Yeung, M.K. Molecular and genetic analyses of *Actinomyces* spp. *Crit Rev Oral Biol Med.*
676 10(2): 120-38. 1999.
- 677 104. Nair, S.P., S. Meghji, M. Wilson, et al. Bacterially induced bone destruction: mechanisms
678 and misconceptions. *Infect Immun.* 64(7): 2371-80. 1996.
- 679 105. Pap, T., A. Claus, S. Ohtsu, et al. Osteoclast-independent bone resorption by fibroblast-
680 like cells. *Arthritis Res Ther.* 5(3): R163-73. 2003.
- 681 106. Mundy, G.R. and F. Elefteriou. Boning up on ephrin signaling. *Cell.* 126(3): 441-3. 2006.
- 682 107. Zhao, C., N. Irie, Y. Takada, et al. Bidirectional ephrinB2-EphB4 signaling controls bone
683 homeostasis. *Cell Metab.* 4(2): 111-21. 2006.
- 684 108. Khamaisi, M., E. Regev, N. Yarom, et al. Possible association between diabetes and
685 bisphosphonate-related jaw osteonecrosis. *J Clin Endocrinol Metab.* 92(3): 1172-5. 2007.
- 686 109. Wessel, J.H., T.B. Dodson, and A.I. Zavras. Zoledronate, smoking, and obesity are
687 strong risk factors for osteonecrosis of the jaw: a case-control study. *J Oral Maxillofac*
688 *Surg.* 66(4): 625-31. 2008.
- 689 110. American Association of Oral and Maxillofacial Surgeons position paper on
690 bisphosphonate-related osteonecrosis of the jaws. *J Oral Maxillofac Surg.* 65(3): 369-76.
691 2007.
- 692
- 693

Figure 1a
[Click here to download high resolution image](#)




Figure 1a

Figure 1b
[Click here to download high resolution image](#)




Figure 1b

Figure 1c
[Click here to download high resolution image](#)




Figure 1c

Figure 2
[Click here to download high resolution image](#)




Figure 2

Figure 3
[Click here to download high resolution image](#)




Figure 3

Figure 4
[Click here to download high resolution image](#)




Figure 4

Figure 5
[Click here to download high resolution image](#)




Figure 5

Figure 6
[Click here to download high resolution image](#)




Figure 6